Dana-Farber Cancer Institute

Boston, Massachusetts, USA | July 16, 2026 Dana-Farber Cancer Institute researchers have identified CDK8 as a promising therapeutic target...

LEXINGTON, Mass., July 6, 2026 Agenus announced new three-year follow-up results from the fully enrolled Phase 1b C-800-01 study...